SBC · SBC Medical Group Holdings Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $38M | 1H 2026 | — |
| Adjusted EBITDA margin non-GAAP | 42% | Six Months Ended June 30, 2026 | — |
| Average spend per visit | $287 | Q2 2026 | — |
| last-twelve-month number of visits | 6.9M | LTM ended June 30, 2026 | — |
| number of locations | 287 | As of the end of June 2026 | — |
| ROE (Annualized) | 16% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Consulting Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SBC
this stock
SBC Medical Group Holdings Inc
|
$503.95M | +17.6% | -15.5% | — | 0.7% |
|
VRSK
Verisk Analytics, Inc.
|
$22.17B | -24.7% | +6.6% | 25.8 | 3.5% |
|
EFX
Equifax Inc
|
$17.40B | -35.6% | +6.9% | 26.0 | 6.6% |
|
BAH
Booz Allen Hamilton Holding Corp
|
$8.39B | -16.5% | -6.4% | 10.9 | 6.0% |
|
FCN
Fti Consulting, Inc
|
$3.71B | -17.0% | +2.4% | 16.3 | 11.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SBC | +6.7% | +19.9% | +22.2% | +2.6% | +17.6% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +7.2% | +20.0% | +9.7% | +2.5% | +5.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.